# US 2024/0392369 A1 · Nucleic acid circularization and amplification on a surface

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0392369 A1
- Document ID: US20240392369A1
- Status: Published application
- Kind: A1
- Application number: 18/776,983
- Filed: 2024-07-18
- Published: 2024-11-28
- Earliest claimed: 2020-10-22
- Assignees: Singular Genomics Systems, Inc.
- Applicants: Singular Genomics Systems, Inc.
- Inventors: Daan Witters; Eli N. Glezer; Andrew King; Sabrina Shore; Ryan Shultzaberger
- Web page: https://patentgrep.com/patent/US20240392369A1

## CPC

- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed herein, inter alia, are compositions and methods for amplification and sequencing of nucleic acids.

## Claims

### Claim 1

A method of sequencing a gap sequence, said method comprising:
(i) hybridizing a first end of a polynucleotide to a first sequence of a splint oligonucleotide, and hybridizing a second end of the polynucleotide to a second sequence of the splint oligonucleotide, wherein the splint oligonucleotide is immobilized to a solid support and comprises the gap sequence between the first sequence and the second sequence;
(ii) extending the polynucleotide along the gap sequence to generate a complement of the gap sequence, and ligating the complement of the gap sequence to the polynucleotide thereby forming a circular polynucleotide;
(iii) extending the splint oligonucleotide to generate an amplification product;
(iv) hybridizing a primer to the amplification product and binding a nucleotide analogue to the primer, wherein the nucleotide analogue is associated with a fluorophore; and
(v) detecting the fluorophore.

### Claim 2 (depends on 1)

The method of claim 1, wherein the amplification product comprises a plurality of complements of the circular polynucleotide.

### Claim 3 (depends on 1)

The method of claim 1, wherein the amplification product comprises a poly (T) sequence.

### Claim 4 (depends on 1)

The method of claim 1, wherein the amplification product comprises 10 consecutive thymidine nucleotides.

### Claim 5 (depends on 1)

The method of claim 1, wherein the amplification product comprises a barcode sequence.

### Claim 6 (depends on 1)

The method of claim 1, wherein the amplification product comprises two different primer binding sequences.

### Claim 7 (depends on 1)

The method of claim 1, wherein the solid support is a bead or substantially planar.

### Claim 8 (depends on 1)

The method of claim 1, wherein the solid support comprises a plurality of splint oligonucleotides randomly distributed on the solid support.

### Claim 9 (depends on 1)

The method of claim 1, wherein the solid support comprises a polymer, wherein the splint oligonucleotide is covalently attached to the polymer.

### Claim 10 (depends on 1)

The method of claim 1, wherein extending the splint oligonucleotide comprises incubating the splint oligonucleotide with a strand-displacing polymerase (a) for about 1 minute to about 2 hours, and/or (b) at a temperature of about 20° C. to about 50° C.

### Claim 11 (depends on 1)

The method of claim 1, further comprising hybridizing the amplification product to a second oligonucleotide attached to the solid support.

### Claim 12 (depends on 11)

The method of claim 11, wherein said second oligonucleotide is attached to the solid support at a 5′-end, and comprises a blocking group at a 3′ end that prevents polymerase extension.

### Claim 13 (depends on 1)

The method of claim 1, wherein the nucleotide analogue further comprises a reversible terminator moiety.

### Claim 14 (depends on 13)

The method of claim 13, wherein the reversible terminator moiety comprises an azido moiety, a disulfide moiety, or an allyl moiety.

### Claim 15 (depends on 3)

The method of claim 3, prior to (i), the method comprises contacting the solid support with a sample comprising cells.

### Claim 16 (depends on 3)

The method of claim 3, prior to (i), the method comprises contacting the solid support with a tissue sample.

### Claim 17 (depends on 1)

The method of claim 1, wherein the solid support is in a flow cell.

### Claim 18 (depends on 1)

The method of claim 1, wherein the gap sequence is 2 to 150 nucleotides.

### Claim 19 (depends on 13)

The method of claim 13, comprising one or more sequencing cycles, each cycle comprising: (a) incorporating the nucleotide analogue into the primer with a polymerase to form an extended primer, (b) contacting the incorporated nucleotide with a deblocking agent to remove the reversible terminator, and (c) binding a nucleotide analogue associated with a fluorophore to the extended primer and detecting the fluorophore.

### Claim 20 (depends on 19)

The method of claim 19, comprising 25 sequencing cycles.
